SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

600196

CNE000000X38

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 15/07/2024 am IST			5-day change	1st Jan Change
22.49 ^CNY	-0.44%		+2.69%	-10.15%

12/07	Fosun Pharma Receives Offers for Share Alternative Offer Related to Henlius Merger Offer	MT
08/07	Shanghai Fosun Pharmaceutical (Group) Cancer Treatment Gets NMPA's Nod for Clinical Trials	MT

Tranche Update on Shanghai Fosun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on March 27, 2024.

July 03, 2024

From April 1, 2024 to June 30, 2024, the company has repurchased 1,457,800 shares, representing 0.05% for CNY 32.32 million. With this, the company has completed the repurchase of 1,457,800 shares, representing 0.05% for CNY 32.32 million under the buyback announced on March 27, 2024.

Latest news about Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Fosun Pharma Receives Offers for Share Alternative Offer Related to Henlius Merger Offer	12/07	MT
Shanghai Fosun Pharmaceutical (Group) Cancer Treatment Gets NMPA's Nod for Clinical Trials	08/07	MT
Shanghai Fosun Pharmaceutical Unit Gets Marketing Approval for Epilepsy Drug in China	08/07	MT
Tranche Update on Shanghai Fosun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on March 27, 2024.	03/07	CI
Shanghai Fosun Pharmaceutical Co., Ltd. Announces Board and Board Committee Changes	01/07	CI
Shanghai Fosun Pharmaceutical Gets Registration Application Approval for Chest Pain Drug	28/06	MT
Shanghai Fosun Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year Ended 31 December 2023, Payable on 23 August 2024	26/06	CI
Hong Kong Stocks Rebound After 3 Days in Red on Rate Cut Hopes; Henlius Soars 19% on Merger Offer	25/06	MT
Henlius Biotech Shares Surge After Fosun's Buyout Offer	25/06	DJ
Fosun Pharma Signs HK$13.4 Billion Merger Offer for Henlius Biotech; Henlius Shares Soar 19%	25/06	MT
Shanghai Fosun Pharmaceutical Co., Ltd. agreed to acquire 40.44% stake in Shanghai Henlius Biotech, Inc..	24/06	CI
Fosun Pharma Trims Stake in Gland Pharma to 51.83%	20/06	MT
Shanghai Fosun Pharmaceutical Co., Ltd. Announces Executive and Committee Changes	19/06	CI
Chinese Regulator Accepts Fosun Pharma Unit's Drug Registration Application for Luvometinib Tablets; Shares Up 3%	07/06	MT
Shanghai Fosun Pharmaceutical Buys Remaining 49% Stake in Nursing Home; Shares Rise 7%	03/06	MT
Shanghai Fosun Pharmaceutical (Group)'s Investigational New Drug Application Accepted by NMPA	27/05	MT
Fosun Pharma Unit Fosun Health to Receive Capital Injection from Foshan Chanxi City Investment	15/05	MT
China Approves Clinical Trials For Breast Cancer Drugs	15/05	MT
Fosun Pharma Unit Gets China Marketing Approval for Schizophrenia Tablets	10/05	MT
Shanghai Fosun Pharmaceutical Unit Secures China Nod to Sell Schizophrenia Drug	09/05	MT
US FDA Grants Clinical Trial Approval for Fosun Unit's Gastric Cancer Tablets	07/05	MT
Fosun Pharma's Q1 Profit Slumps 38%	30/04	MT
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04	CI
Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator	24/04	MT
China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy	18/04	MT

Chart Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Duration

Period

Chart Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

More charts

Company Profile

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a pharmaceutical group organized around 4 areas of activities: - research, development and manufacturing of medicines (72.1% of net sales): for the treatment of cardiovascular diseases, digestive tract, metabolism, central nervous system and blood system disorders, and infectious diseases; - sale of medical equipments and diagnosis products (17.3%); - medical and hospital services (10.5%); - other (0.1%). China accounts for 72.9% of net sales.

Sector

Pharmaceuticals

Calendar

28/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

22.49 CNY

Average target price

28.61 CNY

Spread / Average Target

+27.20%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.	-10.15%	7.51B
ELI LILLY AND COMPANY	+63.05%	856B
NOVO NORDISK A/S	+39.42%	631B
JOHNSON & JOHNSON	-4.78%	359B
MERCK & CO., INC.	+17.52%	325B
ABBVIE INC.	+8.43%	297B
ASTRAZENECA PLC	+14.19%	244B
ROCHE HOLDING AG	+5.81%	234B
NOVARTIS AG	+16.77%	226B
AMGEN INC.	+14.63%	177B

Other Pharmaceuticals

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Equities

600196

CNE000000X38

Pharmaceuticals

Tranche Update on Shanghai Fosun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on March 27, 2024.

EPS Revisions